Combined Use of Lactic-Acid-Producing Bacteria As Probiotics and Rotavirus Vaccine Candidates Expressing Virus-Specific Proteins Publisher Pubmed



Afchangi A¹ ; Latifi T¹ ; Jalilvand S¹ ; Marashi SM¹ ; Shoja Z²
Source: Archives of Virology Published:2021

Abstract

Due to the lower efficacy of currently approved live attenuated rotavirus (RV) vaccines in developing countries, a new approach to the development of safe mucosally administered live bacterial vectors is being considered, using probiotic bacteria as an efficient delivery platform for heterologous RV antigens. Lactic acid bacteria (LAB), which are considered food-grade bacteria and normal microbiota, have been utilized throughout history as probiotics and developed since the 1990s as a delivery system for recombinant heterologous proteins. Over the last decade, LAB have frequently been used as a platform for the delivery of various RV antigens to the mucosa. Given the appropriate safety profile for neonates and providing the benefits of probiotics, recombinant LAB-based vaccines could potentially address the need for a subunit RV vaccine. The present review focuses mainly on different recombinant LAB vaccine constructs for RV and their potential as an alternative recombinant vaccine against RV disease. © 2021, The Author(s), under exclusive licence to Springer-Verlag GmbH, AT part of Springer Nature.